Abstract
Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.
MeSH terms
-
Anti-Bacterial Agents* / pharmacology*
-
Clostridioides difficile / drug effects*
-
Depsipeptides*
-
Dose-Response Relationship, Drug
-
Drug Resistance, Microbial
-
Glycopeptides / pharmacology*
-
Humans
-
Microbial Sensitivity Tests
-
Peptides, Cyclic / pharmacology
-
Ristocetin / analogs & derivatives
-
Teicoplanin
-
Vancomycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Depsipeptides
-
Glycopeptides
-
Peptides, Cyclic
-
ramoplanin
-
MDL 62873
-
Ristocetin
-
Teicoplanin
-
Vancomycin
-
teicoplanin aglycone